Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-115 plus latanoprost in POAG or ocular hypertension
jRCT2080222237Phase 3
- Sponsor
- Kowa Company, Ltd.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing K-115 add-on to latanoprost with Placebo add-on to latanoprost (2 arms). Primary endpoint: Intraocular pressure fluctuations.
02
Drugs
ripasudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080222237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222237.